Alibaba Health's Long-Term Growth Remains Intact -- Market Talk

Dow Jones05-20 16:40

0840 GMT - Alibaba Health Information Technology's long-term growth remains intact despite near-term moderation in profit growth, say UOB Kay Hian's Sunny Chen and Carol Dou in a note. The analysts see structural growth opportunities for the healthcare subsidiary of Alibaba Group, buoyed by sustained innovative-drug momentum, expanding artificial-intelligence adoption, and deeper synergy with the Alibaba ecosystem. They project the company's FY 2026-2028 revenue and adjusted net profit to grow at compound annual growth rates of 12% and 15%, respectively. Still, UOB KH cuts its target price to HK$5.20 from HK$6.00 to reflect faster investment in innovative drugs and AI. The brokerage retains its buy rating. Shares closed 2.0% lower at HK$3.91. (megan.cheah@wsj.com)

 

(END) Dow Jones Newswires

May 20, 2026 04:40 ET (08:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment